Really, the PSA trial is over so cash burn on this is very minimal if any. IND for HOT prostate is coming soon, so this is not going to be scrapped especially as the results were good.
You talk about cash burn, well if HOT was showing very similar results as NEO would you not think it prudent in relation to cash burn to just go with HOT into combo portion of the trial. Why would you run 2 trials when mono results were the similar.
News 
Market Data 
Discover 
